Purpose
The overall goal of the Cancer Pharmacokinetics and Pharmacodynamics Core (CPPC) is to provide a high-quality resource and state-of-the-art services for measuring pharmacokinetic drug levels of novel and standard chemotherapeutic agents in preclinical animal studies and in clinical studies, and to quantify pharmacodynamic endpoints in preclinical studies as well as for early phase clinical trials. Drug quantitation is achieved through liquid chromatography-tandem mass spectrometry workflows using biological fluids (e.g., blood, serum, urine) and other tissues, including tumors. These measurements can be taken further downstream to produce useful pharmacokinetic data.
Molecular endpoints are obtained through select core immunoassay services using whole cells, cell/tumor extracts or biological fluids. High-throughput, cell-based drug screening assays with multidrug synergy analysis can be used in a preclinical setting or as part of clinical correlative studies. Additional services supporting pre-clinical experimentation include cell-line drug quantitation and pharmacokinetic analysis. Major technical services offered by CPPC are Drug Quantitation, Pharmacokinetic Analysis, Drug Response Assays and Pharmacodynamic Analytical Services.
The CPPC offers a full line of services within these major categories and the ability to work with investigators through collaborative design, to develop and implement both translational science and clinical science experiments in the core under the umbrella of services. In addition, a major function of the CPPC is dedicated to consultation services to Members ranging from experimental design to interpretation of data. The core consists of five full-time highly trained staff members. These kinetic and dynamic services provide cancer center members with invaluable resources to conduct research and play a significant role in establishing the cancer center as a leader in clinical and translational research.
Services
CPPC services include specialized sample processing for research specimens collected in clinical trials and a variety of pharmacologic, whole cell-based and molecular assays:
Pharmacokinetic Services
Drug Quantitation (free and total)
Clinical Research
Pre-clinical (murine)
Metabolic Stability/Inhibition Studies
Basic Science (cell lines)
Pharmacokinetic Analysis
Non-Compartmental & Compartmental Analysis
Pharmacodynamic Services
Molecular Endpoint Analysis
Hematologic Subset Enrichment
Flow/PhosFlow Setup
Western Blotting/EMSA
ELISA and CBA/Luminex Setup
Drug Screening/Drug Interaction Analysis
384- and 1536-well Plate - Cell Based Assays
Viability/Cytotoxicity/Apoptosis IC50 Analysis
Drug Synergy/Antagonism Analysis (EoHSA/CI)
Please contact the Core by phone or email for more details on current services and pricing.
Scientific Directors:
Andrii Monastyrskyi, PhD
andrii.monastyrskyi@moffitt.org
Office: 813-745-3660
Nelli Bejanyan, MD
nelli.bejanyan@moffitt.org
Office: 813-745-6008
Manager, Translational Sciences Shared Resources:
Anthony Neuger, MS
anthony.neuger@moffitt.org
813-745-2288
Pharmacokinetic Services:
Sr. Staff Scientist - Mohan Kumar Muthu Karuppan, PhD
mohankumar.muthukaruppan@moffitt.org
813-745-2124
Staff Scientist - Samer Sansil, MS
samer.sansil@moffitt.org
813-745-5759
Pharmacodynamic Services:
Staff Scientist - Chris Cubitt, PhD
christopher.cubitt@moffitt.org
813-745-3687
Core Staff:
Research Specialist - Shumin Zhang, MD
Research Specialist - Ashley Blanchard, BS
Location
The Cancer Pharmacokinetics and Pharmacodynamics Core is located in the Moffitt Research Center (MRC) on the first floor, rooms 1304 & 1305.
Scheduling
The Cancer Pharmacokinetics and Pharmacodynamics Core uses a Laboratory Information Management Suite (LIMS) located on the Moffittnet for billing and usage tracking.
Publications
All publications based on work conducted in the Cancer Pharmacokinetics and Pharmacodynamics Core should acknowledge the facility. A suggested statement is as follows:
This work has been supported in part by the Cancer Pharmacokinetics and Pharmacodynamics Core at the H. Lee Moffitt Cancer Center & Research Institute, a comprehensive cancer center designated by the National Cancer Institute and funded in part by Moffitt’s Cancer Center Support Grant (P30-CA076292)
If a Core Staff member(s) significantly contributes or participates in a project, investigators are encouraged to consider including the individual(s) in the list of authors.
